Literature DB >> 15096373

CD30(+) cutaneous lymphoma in association with atopic eczema.

Clair L Fletcher1, Guy E Orchard, Virginia Hubbard, Sean J Whittaker, Richard L Edelson, Robin Russell-Jones.   

Abstract

BACKGROUND: Chronic atopic eczema is not regarded as a precursor of malignancy, and, to our knowledge, there has been only one previous case report of CD30(+) cutaneous lymphoma in association with atopic dermatitis. OBSERVATIONS: We report 4 cases of CD30(+) lymphoproliferative disease in young adult patients with active atopic eczema dating from early childhood. Three patients developed primary cutaneous anaplastic large cell lymphoma, of whom 2 developed systemic disease and 1 died. The other patient developed lymphomatoid papulosis type A, which resolved after withdrawal of cyclosporine therapy. No other patient had received immunosuppressive therapy. Three had been treated with phototherapy, and 2 of these patients exhibited positive immunostaining for p53 within a proportion of the tumor cell population.
CONCLUSIONS: Although we have not been able to establish a causative link, we believe that the association of these 2 conditions has not occurred by chance. Biopsies of lesional skin from subjects with atopic eczema exhibit a proportion of CD30 cells, and clonal transformation of this subpopulation might account for the CD30(+) lymphomas in our patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096373     DOI: 10.1001/archderm.140.4.449

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

1.  Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.

Authors:  Maria Estela Martinez-Escala; Alba L Posligua; Heather Wickless; Audrey Rutherford; Kimberly A Sable; Belen Rubio-Gonzalez; Xiaolong A Zhou; Jason B Kaplan; Barbara Pro; Jaehyuk Choi; Christiane Querfeld; Steven T Rosen; Joan Guitart
Journal:  J Am Acad Dermatol       Date:  2018-01-04       Impact factor: 11.527

2.  [Loss of appetite, night sweats, eczema, and axillary and inguinal lymph node swelling in a 28-year-old man].

Authors:  U Wahl; R Stranzenbach; I Tischoff; A Tannapfel; R Stadler; F Ernst
Journal:  Internist (Berl)       Date:  2014-03       Impact factor: 0.743

Review 3.  Primary cutaneous anaplastic large cell lymphoma occurring in an atopic dermatitis patient: a case report with review of the literature with emphasis on their association.

Authors:  Mitsuaki Ishida; Keiko Hodohara; Miyuki Yoshii; Hiroko Okuno; Akiko Horinouchi; Ayaka Shirakawa; Ayumi Harada; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Takashi Yoshida; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

4.  [Clinical course and therapy of lymphomatoid papulosis. Experience with 17 cases and literature review].

Authors:  D Korpusik; T Ruzicka
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

5.  Recurrent lymphomatoid papulosis associated with nephrotic syndrome. An occurrence of uncertain origin.

Authors:  Gian Marco Ghiggeri; Dario Bleid; Alberto Garaventa; Cristina Coccia; Claudio Gambini; Gianluca Caridi; Francesco Perfumo
Journal:  Pediatr Nephrol       Date:  2007-11-20       Impact factor: 3.714

6.  Primary cutaneous anaplastic large cell lymphoma arising from a long-standing erythema nodosum: A case report.

Authors:  Liang-Liang Ma; Shi-Xin Han; Mei-Yun Fang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

7.  Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report.

Authors:  Ricardo Garcia Pastorello; Felipe D'Almeida Costa; Cynthia A B T Osório; Fabiana B A Makdissi; Stephania Martins Bezerra; Marina de Brot; Antonio Hugo J F M Campos; Fernando Augusto Soares; José Vassallo
Journal:  Diagn Pathol       Date:  2018-01-25       Impact factor: 2.644

8.  Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder.

Authors:  Marshall E Kadin; Robert G Hamilton; Eric C Vonderheid
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.